Loading clinical trials...
Loading clinical trials...
A Phase I Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of BI 1026706 Administered Orally as Tablets Twice Daily for 4 Weeks to Patients With COPD in Order to Evaluate Safety, Tolerability, Pharmacokinetics and Effect on Inflammation
Conditions
Interventions
BI 1026706
Placebo
+1 more
Locations
10
Denmark
Bispebjerg og Frederiksberg Hospital
København NV, Denmark
Odense University Hospital
Odense C, Denmark
PAREXEL International GmbH
Berlin, Germany
IKF Pneumologie GmbH & Co. KG
Frankfurt, Germany
Inamed GmbH
Gauting, Germany
Pneumologisches Forschungsinstitut an der LungenClinic Grosshansdorf GmbH
Großhansdorf, Germany
Start Date
January 25, 2016
Primary Completion Date
June 14, 2016
Completion Date
June 14, 2016
Last Updated
August 5, 2019
NCT06831994
NCT02755974
NCT05050591
NCT05913765
NCT05592847
NCT00683722
Lead Sponsor
Boehringer Ingelheim
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions